" class="no-js "lang="en-US"> Illumina Archives - Medtech Alert
Thursday, March 28, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Illumina and GenoScreen Launch Next Generation Sequencing Innovation to Eliminate Tuberculosis in Africa

Illumina, a global leader in DNA sequencing and array-based technologies, and GenoScreen, an innovative genomics […]

Illumina and Myriad Genetics Expand Partnership to Broaden Access to HRD Testing in the United States

Illumina, a global leader in DNA sequencing and array-based technologies, and Myriad Genetics, a leader […]

Illumina Introduces New Pan-Cancer Companion Diagnostic to Match Patients with Rare Genetic Mutations to Targeted Therapy

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the […]

Illumina and Allegheny Health Network to Assess In-House Comprehensive Cancer Genomic Profiling to Enhance Patient Care

Illumina, Inc. (NASDAQ: ILMN) a global leader in DNA sequencing and array-based technologies, and Allegheny Health […]

Illumina and Boehringer Ingelheim Announce Companion Diagnostic Partnership

Illumina Inc. (NASDAQ: ILMN) today announced a partnership with Boehringer Ingelheim to develop companion diagnostics (CDx) […]

SomaLogic Announces Exclusive Partnership with Illumina to Develop Sequencing-based Proteomic Solutions

SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced a worldwide strategic collaboration […]

BICO Announces Appointment of Susan Tousi as New Member of the Board of Directors

Today BICO, the world’s leading Bio Convergence company announced it has added Susan Tousi to […]

Whole Genome Sequencing Improves Diagnosis of Rare Diseases and Shortens Diagnostic Journeys for Patients, According to World First Study

A world-first scientific study, published today in the New England Journal of Medicine, has shown that […]

Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL

Illumina, Inc. (NASDAQ:ILMN) today announced that Bob Ragusa has been appointed as Chief Executive Officer of GRAIL, […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more